Trial Profile
HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Tivanisiran (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms HELIX
- Sponsors Sylentis
- 06 May 2019 Results published in a Sylentis Media Release.
- 12 Feb 2019 Status changed from active, no longer recruiting to completed.
- 31 Jan 2019 According to a Sylentis media release, data from the study will be presented at the Annual Congress of the Association for Research in Vision and Ophthalmology, ARVO 2019.